Novo Nordisk's Alzheimer's trial really is like a lottery ticket. If it wins, the company gains a transformational new market ...
Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...
Former Trump administration national security adviser John Bolton has been charged in a federal investigation into the ...
AI and SPARK platform integration accelerates cancer research by analyzing diverse health data for early detection and ...
RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and BioVie, Inc. (Nasdaq:BIVI) on the ...
REDMOND, Wash. and PRINCETON, N.J., Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers ...
OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug ...
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s ...
Eli Lilly and Company today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) ...
TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox ...
The article discusses sexual assault. If they hadn’t met in prison, none of it would have happened like this. On the outside, ...
Patients who had adjuvant Verzenio with endocrine therapy had a small but significant improvement in survival versus endocrine therapy alone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback